CLAIMS

1. A pharmaceutical composition for treatment of pain, which comprises in combination a benzothiadiazole derivative of formula I



I

wherein each R1, R2 and R3 independently, is hydrogen, halogen, C_1-C_7 alkyl, C_1-C_7 alkoxy, nitro, cyano, hydroxy or C_1-C_7 alkylthio;
and a COX-2 inhibitor for simultaneous, sequential or separate use.

2. Use of a COX-2 inhibitor for the preparation of a medicament, for use in combination with a benzothiadiazole derivative of formula I as defined in claim 1, for treatment of pain.

3. Use of a benzothiadiazole derivative of formula I as defined in claim 1, for the preparation of a medicament for use in combination with a COX-2 inhibitor for treatment of pain.

4. A method of treating a patient suffering from pain comprising administering to the patient an effective amount of a benzothiadiazole derivative of formula I as defined above, and an effective amount of a COX-2 inhibitor.

5. A package comprising a benzothiadiazole derivative of formula I as defined in claim 1, together with instructions for use in combination with a COX-2 inhibitor for treatment of pain, or

a package comprising a COX-2 inhibitor together with instructions for use in combination with a benzothiadiazole derivative of formula I as defined in claim 1, for treatment of pain.

6. A composition method, use or package according to any one of the preceding claims in which the COX-2 inhibitor is selected from the group consisting of rofecoxib, etoricoxib, celecoxib, valdecoxib, parecoxib, or a 5-alkyl-2-arylaminophenylacetic acid derivative COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.

7. A composition method, use or package according to claim 7, in which the COX-2 inhibitor is a compound of formula V



(V)

wherein R is methyl or ethyl;

R_1 is chloro or fluoro;

R_2 is hydrogen or fluoro;

R_3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;

R_4 is hydrogen or fluoro; and

R_5 is chloro, fluoro, trifluoromethyl or methyl,

or a pharmaceutically acceptable salt or ester thereof.

8. A composition method, use or package according to claim 8 in which the COX-2 inhibitor is 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid,

or a pharmaceutically acceptable salt or ester thereof.

9. A composition method, use or package according to any one of the preceding claims in which the benzothiadiazole derivative is 5-chloro-4-(2-imidazol-2-ylamino)-2,1,3-benzothiadiazole.